Vir Bio Secures $1.7B+ Astellas Oncology Partnership & Reports Strong Phase 1 Prostate Cancer Data

summarizeSummary

Vir Biotechnology announced a major collaboration with Astellas for its lead prostate cancer drug, VIR-5500, securing significant funding and reporting strong Phase 1 clinical results, extending its financial runway.

check_boxKey Events

• Global Strategic Collaboration for VIR-5500

  Vir Biotechnology entered into a global strategic collaboration and license agreement with Astellas US LLC to co-develop and co-commercialize VIR-5500, a Phase 1 PRO-XTEN® dual-masked T-cell engager for prostate cancer.

• Significant Upfront & Milestone Payments

  Vir Bio will receive $335 million in upfront and near-term milestone payments, including $240 million in cash and a $75 million equity investment. The agreement also includes eligibility for up to $1.37 billion in future development, regulatory, and sales milestones, plus tiered, double-digit royalties on ex-U.S. net sales.

• Astellas Equity Investment at Premium

  Astellas agreed to purchase 7,239,382 shares of Vir Bio common stock for $75 million, at a price of $10.36 per share. This represents a 50% premium to the 30-day volume weighted average price as of February 17, 2026, and is above the company's 52-week high of $9.93.

• Positive Phase 1 Clinical Data for VIR-5500

  Updated Phase 1 results for VIR-5500 monotherapy showed a favorable safety profile with no dose-limiting toxicities and dose-dependent anti-tumor activity, including 82% PSA50 and 45% objective response rates in high-dose cohorts for metastatic prostate cancer patients.

auto_awesomeAnalysis

This 8-K details a highly significant global strategic collaboration between Vir Biotechnology and Astellas for VIR-5500, a prostate cancer therapeutic. The deal provides substantial upfront funding, including a $75 million equity investment at a premium to recent trading prices, and extends Vir Bio's cash runway into Q2 2028. Concurrently, the company reported compelling Phase 1 data for VIR-5500, showing a favorable safety profile and strong anti-tumor activity in heavily pre-treated patients. This combination of strategic validation, significant non-dilutive funding, and positive clinical progress substantially de-risks the company's lead oncology program and strengthens its financial position.